Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol-Reference-Cited by-同舟云学术

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Published:2021-09-24 Issue: Volume:12 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Sablerolles Roos S. G.,Goorhuis Abraham,GeurtsvanKessel Corine H.,de Vries Rory D.,Huckriede Anke L. W.,Koopmans Marion P. G.,Lafeber Melvin,Postma Douwe F.,van Baarle Debbie,Visser Leo G.,Dalm Virgil A. S. H.,Kootstra Neeltje A.,Rietdijk Wim J. R.,van der Kuy P. Hugo M.

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference18 articles.

1. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine;Sadoff;N Engl J Med,2021

2. Safety and Efficacy of the Chadox1 Ncov-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

3. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine;Baden;N Engl J Med,2021

4. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine;Polack;N Engl J Med,2020

5. Could Mixing COVID Vaccines Boost Immune Response;Ledford;Nature,2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study;The Lancet Regional Health - Southeast Asia;2024-03

2. What every intensivist should know about: The value of limitations in clinical research;Journal of Critical Care;2023-11

3. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial;The Lancet Infectious Diseases;2023-08

4. Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?;Frontiers in Public Health;2023-01-26

5. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination;iScience;2023-01